Share Price and Basic Stock Data
Last Updated: January 3, 2026, 1:58 pm
| PEG Ratio | 33.34 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hindustan Bio Sciences Ltd operates in the Trading & Distributors industry, with a current price of ₹5.78 and a market capitalization of ₹5.92 Cr. The company reported a total sales figure of ₹0.92 Cr for the fiscal year ending March 2023, which reflected a modest increase compared to ₹0.43 Cr in March 2022. However, the sales trajectory has shown significant fluctuations, with quarterly sales ranging from ₹0.00 Cr in June 2023 to a peak of ₹0.33 Cr in March 2023. Over the past few quarters, the company has struggled with sales in certain periods, notably recording zero revenues in June 2023 and September 2024. This inconsistency in revenue generation raises concerns about the sustainability of its business operations. The trailing twelve months (TTM) sales stood at ₹0.70 Cr, indicating a need for strategic direction to enhance revenue stability and growth.
Profitability and Efficiency Metrics
Hindustan Bio Sciences Ltd reported a net profit of ₹0.02 Cr for the fiscal year ending March 2023, with an operating profit margin (OPM) of 0.00%, indicating that operational costs are consuming all revenues. The company’s profitability metrics have shown volatility; for instance, the operating profit margin fluctuated significantly, achieving a high of 26.32% in March 2025, yet it also recorded negative margins in previous quarters. The return on equity (ROE) was reported at 11.8%, which is relatively low compared to other sectors, while the return on capital employed (ROCE) stood at just 2.95%. Additionally, the cash conversion cycle (CCC) was reported at 198.27 days, suggesting inefficiencies in managing receivables and inventory. The company must focus on improving its operational efficiency to enhance profitability and ensure sustainable growth.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hindustan Bio Sciences Ltd presents a mixed picture. The company reported total borrowings of ₹2.62 Cr and reserves of -₹1.19 Cr, indicating a negative equity position. The current ratio stood at an extraordinary 73.31, suggesting that the company has substantial liquidity to cover its short-term obligations, which is significantly higher than typical sector norms. However, such a high ratio may also indicate inefficiency in utilizing assets for revenue generation. The interest coverage ratio (ICR) was reported at 71.29x, showcasing the company’s ability to cover its interest expenses comfortably, which is a positive sign. Nevertheless, the price-to-book value (P/BV) ratio of 7.91x indicates that the stock may be overvalued relative to its net assets. The company must address its negative reserves while maintaining liquidity to bolster its financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hindustan Bio Sciences Ltd reveals a significant public ownership of 87.81% as of March 2025, with promoters holding 12.19%. This distribution suggests a broad base of retail investors, which can be seen as a strength in terms of market confidence. The total number of shareholders has increased from 8,879 in December 2022 to 11,405 in September 2025, indicating growing investor interest. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may limit the stock’s liquidity and perceived stability. The consistent promoter holding over the periods reflects a commitment to the company, yet the low institutional participation could raise concerns about the long-term confidence of larger investors. This dynamic may affect the company’s stock performance and overall market perception.
Outlook, Risks, and Final Insight
Hindustan Bio Sciences Ltd faces several risks, including its inconsistent revenue generation and negative reserves, which could challenge its operational stability. The company’s high liquidity, while a positive factor, may not be effectively translating into growth due to inefficiencies in asset utilization. On the upside, the recent improvement in profitability metrics, such as the operating profit margin reaching 26.32% in March 2025, indicates potential for recovery and growth. The increasing number of shareholders suggests a rising interest in the company, but the lack of institutional backing remains a concern. To foster a more favorable outlook, Hindustan Bio Sciences Ltd needs to focus on enhancing operational efficiencies, stabilizing revenue streams, and improving its financial structure. The company’s future performance will depend on its ability to navigate these challenges and capitalize on its strengths.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MKP Mobility Ltd | 42.6 Cr. | 125 | 226/103 | 30.0 | 22.3 | 0.00 % | 19.6 % | 4.35 % | 10.0 |
| Mrugesh Trading Ltd | 1.43 Cr. | 5.84 | 5.84/0.48 | 277 | 0.00 % | 4.43 % | 3.81 % | 1.00 | |
| Mukta Agriculture Ltd | 5.98 Cr. | 2.76 | 5.34/2.52 | 10.2 | 0.00 % | 0.57 % | 0.63 % | 10.0 | |
| Muller and Phipps (India) Ltd | 15.0 Cr. | 240 | 385/208 | 188 | 22.9 | 0.00 % | % | % | 10.0 |
| Hindustan Bio Sciences Ltd | 5.92 Cr. | 5.78 | 10.3/5.00 | 296 | 0.84 | 0.00 % | 2.95 % | 11.8 % | 2.00 |
| Industry Average | 261.00 Cr | 113.48 | 299.82 | 62.11 | 0.00% | 6.43% | 5.06% | 7.57 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.27 | 0.00 | 0.32 | 0.33 | 0.00 | 0.32 | 0.32 | 0.39 | 0.41 | 0.00 | 0.00 | 0.38 | 0.32 |
| Expenses | 0.29 | 0.07 | 0.27 | 0.31 | 0.12 | 0.26 | 0.26 | 0.35 | 0.34 | 0.05 | 0.04 | 0.28 | 0.32 |
| Operating Profit | -0.02 | -0.07 | 0.05 | 0.02 | -0.12 | 0.06 | 0.06 | 0.04 | 0.07 | -0.05 | -0.04 | 0.10 | 0.00 |
| OPM % | -7.41% | 15.62% | 6.06% | 18.75% | 18.75% | 10.26% | 17.07% | 26.32% | 0.00% | ||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.07 | 0.05 | 0.02 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.03 | -0.07 | 0.05 | 0.01 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
| EPS in Rs | -0.03 | -0.07 | 0.05 | 0.01 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
Last Updated: August 19, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Hindustan Bio Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.32 Cr.. The value appears to be declining and may need further review. It has decreased from 0.38 Cr. (Mar 2025) to 0.32 Cr., marking a decrease of 0.06 Cr..
- For Expenses, as of Jun 2025, the value is 0.32 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.28 Cr. (Mar 2025) to 0.32 Cr., marking an increase of 0.04 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 26.32% (Mar 2025) to 0.00%, marking a decrease of 26.32%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.11 (Mar 2025) to 0.01, marking a decrease of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.25 | 0.75 | 1.26 | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 1.05 | 0.81 | 0.70 |
| Expenses | 2.96 | 1.97 | 1.38 | 1.48 | 3.38 | 3.43 | 1.80 | 1.97 | 0.94 | 0.95 | 0.99 | 0.71 | 0.70 |
| Operating Profit | -0.71 | -1.22 | -0.12 | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.06 | 0.10 | 0.00 |
| OPM % | -31.56% | -162.67% | -9.52% | -46.53% | -228.16% | 3.65% | 7.22% | -91.26% | -118.60% | -3.26% | 5.71% | 12.35% | 0.00% |
| Other Income | -0.04 | -0.01 | -1.92 | -0.00 | 0.09 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.03 |
| Interest | 0.03 | 0.03 | 0.03 | 0.01 | -0.00 | 0.01 | 0.01 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Depreciation | 0.22 | 0.18 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | -0.00 | 0.01 | 0.01 | -0.00 | 0.00 |
| Profit before tax | -1.00 | -1.44 | -2.08 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.05 | 0.10 | 0.03 |
| Tax % | -0.00% | 0.69% | -0.00% | -0.00% | -0.00% | -0.00% | 33.33% | -2.08% | -0.00% | -0.00% | -0.00% | -0.00% | |
| Net Profit | -0.99 | -1.46 | -2.09 | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.06 | 0.10 | 0.02 |
| EPS in Rs | -0.97 | -1.42 | -2.04 | -0.48 | -2.22 | 0.11 | 0.08 | -0.92 | -0.51 | -0.04 | 0.06 | 0.10 | 0.02 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -47.47% | -43.15% | 76.56% | -365.31% | 104.82% | -27.27% | -1275.00% | 44.68% | 92.31% | 250.00% | 66.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.32% | 119.71% | -441.86% | 470.13% | -132.10% | -1247.73% | 1319.68% | 47.63% | 157.69% | -183.33% |
Hindustan Bio Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 4, 2025, 3:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 2.05 | 2.05 | 2.05 | 2.05 |
| Reserves | -1.83 | -3.34 | -5.43 | -5.92 | -8.20 | -8.09 | -8.01 | -8.95 | -9.46 | -1.30 | -1.25 | -1.15 | -1.19 |
| Borrowings | 0.77 | 0.97 | 0.94 | 1.30 | 1.57 | 3.37 | 2.60 | 1.86 | 2.17 | 2.46 | 2.56 | 2.51 | 2.62 |
| Other Liabilities | 0.48 | 0.17 | 0.12 | 0.24 | 0.09 | 0.10 | 0.71 | 0.32 | 0.02 | 0.08 | 0.01 | 0.01 | 0.02 |
| Total Liabilities | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 | 3.50 |
| Fixed Assets | 0.16 | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.44 |
| CWIP | 1.92 | 1.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 7.59 | 6.05 | 5.81 | 5.81 | 3.65 | 5.57 | 5.50 | 3.44 | 2.94 | 3.26 | 3.34 | 3.39 | 3.06 |
| Total Assets | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 | 3.50 |
Below is a detailed analysis of the balance sheet data for Hindustan Bio Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 2.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.05 Cr..
- For Reserves, as of Sep 2025, the value is -1.19 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -1.15 Cr. (Mar 2025) to -1.19 Cr., marking a decline of 0.04 Cr..
- For Borrowings, as of Sep 2025, the value is 2.62 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 2.51 Cr. (Mar 2025) to 2.62 Cr., marking an increase of 0.11 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.01 Cr. (Mar 2025) to 0.02 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3.50 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.42 Cr. (Mar 2025) to 3.50 Cr., marking an increase of 0.08 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.44 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Mar 2025) to 0.44 Cr., marking an increase of 0.41 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3.06 Cr.. The value appears to be declining and may need further review. It has decreased from 3.39 Cr. (Mar 2025) to 3.06 Cr., marking a decrease of 0.33 Cr..
- For Total Assets, as of Sep 2025, the value is 3.50 Cr.. The value appears strong and on an upward trend. It has increased from 3.42 Cr. (Mar 2025) to 3.50 Cr., marking an increase of 0.08 Cr..
However, the Borrowings (2.62 Cr.) are higher than the Reserves (-1.19 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.48 | -2.19 | -1.06 | -1.77 | -3.92 | -3.24 | -2.46 | -2.80 | -2.68 | -2.49 | -2.50 | -2.41 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 202.78 | 155.73 | 136.15 | 169.85 | 113.40 | 171.22 | 255.88 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Inventory Days | 36.08 | 25.08 | 0.00 | 0.00 | 51.23 | 13.89 | 95.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days Payable | 84.88 | 39.01 | 44.82 | 7.58 | 185.31 | |||||||
| Cash Conversion Cycle | 153.97 | 141.80 | 136.15 | 169.85 | 119.80 | 177.54 | 166.03 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Working Capital Days | 186.56 | 111.93 | -63.73 | -191.53 | -170.10 | 85.10 | 86.55 | -148.83 | -500.81 | -226.14 | 312.86 | 441.60 |
| ROCE % | -9.91% | -16.40% | -1.91% | -8.43% | -49.08% | 2.62% | 2.51% | -23.75% | -16.67% | -1.30% | 1.52% | 2.95% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 |
| Diluted EPS (Rs.) | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 |
| Cash EPS (Rs.) | 0.09 | 0.06 | -0.03 | -0.50 | -0.90 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.88 | 0.78 | 0.72 | 0.76 | 1.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.88 | 0.78 | 0.72 | 0.76 | 1.27 |
| Revenue From Operations / Share (Rs.) | 0.79 | 1.03 | 0.89 | 0.42 | 1.01 |
| PBDIT / Share (Rs.) | 0.09 | 0.06 | -0.02 | -0.49 | -0.91 |
| PBIT / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.49 | -0.92 |
| PBT / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.50 | -0.93 |
| Net Profit / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.50 | -0.91 |
| PBDIT Margin (%) | 12.27 | 6.06 | -3.05 | -117.53 | -91.13 |
| PBIT Margin (%) | 12.24 | 5.41 | -3.67 | -118.32 | -91.91 |
| PBT Margin (%) | 12.07 | 5.06 | -4.11 | -119.47 | -92.57 |
| Net Profit Margin (%) | 12.38 | 5.47 | -4.38 | -120.18 | -91.07 |
| Return on Networth / Equity (%) | 11.12 | 7.16 | -5.41 | -65.75 | -72.04 |
| Return on Capital Employeed (%) | 2.92 | 1.69 | -1.81 | -27.41 | -46.54 |
| Return On Assets (%) | 2.94 | 1.70 | -1.23 | -17.39 | -26.95 |
| Long Term Debt / Equity (X) | 2.77 | 3.18 | 1.50 | 1.36 | 0.56 |
| Total Debt / Equity (X) | 2.77 | 3.18 | 3.29 | 2.75 | 1.42 |
| Asset Turnover Ratio (%) | 0.23 | 0.31 | 0.29 | 0.13 | 0.22 |
| Current Ratio (X) | 73.31 | 69.04 | 0.60 | 0.48 | 0.72 |
| Quick Ratio (X) | 73.31 | 69.04 | 0.60 | 0.48 | 0.72 |
| Interest Coverage Ratio (X) | 71.29 | 17.33 | -6.88 | -101.64 | -136.86 |
| Interest Coverage Ratio (Post Tax) (X) | 72.93 | 16.63 | -8.87 | -102.94 | -135.78 |
| Enterprise Value (Cr.) | 9.65 | 9.95 | 7.81 | 6.48 | 4.92 |
| EV / Net Operating Revenue (X) | 11.86 | 9.45 | 8.47 | 15.06 | 4.77 |
| EV / EBITDA (X) | 96.69 | 155.82 | -277.11 | -12.81 | -5.23 |
| MarketCap / Net Operating Revenue (X) | 8.80 | 7.06 | 5.91 | 10.05 | 2.98 |
| Price / BV (X) | 7.91 | 9.24 | 7.31 | 5.50 | 2.36 |
| Price / Net Operating Revenue (X) | 8.80 | 7.06 | 5.91 | 10.05 | 2.98 |
| EarningsYield | 0.01 | 0.01 | -0.01 | -0.11 | -0.30 |
After reviewing the key financial ratios for Hindustan Bio Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has increased from 0.06 (Mar 24) to 0.09, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.88. It has increased from 0.78 (Mar 24) to 0.88, marking an increase of 0.10.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.88. It has increased from 0.78 (Mar 24) to 0.88, marking an increase of 0.10.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.79. It has decreased from 1.03 (Mar 24) to 0.79, marking a decrease of 0.24.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 2. It has increased from 0.06 (Mar 24) to 0.09, marking an increase of 0.03.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 2. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 12.27. This value is within the healthy range. It has increased from 6.06 (Mar 24) to 12.27, marking an increase of 6.21.
- For PBIT Margin (%), as of Mar 25, the value is 12.24. This value is within the healthy range. It has increased from 5.41 (Mar 24) to 12.24, marking an increase of 6.83.
- For PBT Margin (%), as of Mar 25, the value is 12.07. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 12.07, marking an increase of 7.01.
- For Net Profit Margin (%), as of Mar 25, the value is 12.38. This value exceeds the healthy maximum of 10. It has increased from 5.47 (Mar 24) to 12.38, marking an increase of 6.91.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.12. This value is below the healthy minimum of 15. It has increased from 7.16 (Mar 24) to 11.12, marking an increase of 3.96.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.92. This value is below the healthy minimum of 10. It has increased from 1.69 (Mar 24) to 2.92, marking an increase of 1.23.
- For Return On Assets (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 5. It has increased from 1.70 (Mar 24) to 2.94, marking an increase of 1.24.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 2.77. This value exceeds the healthy maximum of 1. It has decreased from 3.18 (Mar 24) to 2.77, marking a decrease of 0.41.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.77. This value exceeds the healthy maximum of 1. It has decreased from 3.18 (Mar 24) to 2.77, marking a decrease of 0.41.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.23. It has decreased from 0.31 (Mar 24) to 0.23, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 73.31. This value exceeds the healthy maximum of 3. It has increased from 69.04 (Mar 24) to 73.31, marking an increase of 4.27.
- For Quick Ratio (X), as of Mar 25, the value is 73.31. This value exceeds the healthy maximum of 2. It has increased from 69.04 (Mar 24) to 73.31, marking an increase of 4.27.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 71.29. This value is within the healthy range. It has increased from 17.33 (Mar 24) to 71.29, marking an increase of 53.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 72.93. This value is within the healthy range. It has increased from 16.63 (Mar 24) to 72.93, marking an increase of 56.30.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9.65. It has decreased from 9.95 (Mar 24) to 9.65, marking a decrease of 0.30.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 11.86. This value exceeds the healthy maximum of 3. It has increased from 9.45 (Mar 24) to 11.86, marking an increase of 2.41.
- For EV / EBITDA (X), as of Mar 25, the value is 96.69. This value exceeds the healthy maximum of 15. It has decreased from 155.82 (Mar 24) to 96.69, marking a decrease of 59.13.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.80. This value exceeds the healthy maximum of 3. It has increased from 7.06 (Mar 24) to 8.80, marking an increase of 1.74.
- For Price / BV (X), as of Mar 25, the value is 7.91. This value exceeds the healthy maximum of 3. It has decreased from 9.24 (Mar 24) to 7.91, marking a decrease of 1.33.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.80. This value exceeds the healthy maximum of 3. It has increased from 7.06 (Mar 24) to 8.80, marking an increase of 1.74.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hindustan Bio Sciences Ltd:
- Net Profit Margin: 12.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.92% (Industry Average ROCE: 6.43%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.12% (Industry Average ROE: 5.06%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 72.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 73.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 296 (Industry average Stock P/E: 299.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.77
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | H.No.8-2-269/S, Plot No.31, Sagar Co-Operative Housing Society, Hyderabad Telangana 500034 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. J V R Mohan Raju | Chairman & Managing Director |
| Mrs. J Uma | Director |
| Mr. Jaison George | Director |
| Mr. Reji Abraham | Independent Director |
| Mr. B Nagi Reddy | Independent Director |
| Mr. G Prateek Reddy | Independent Director |
FAQ
What is the intrinsic value of Hindustan Bio Sciences Ltd?
Hindustan Bio Sciences Ltd's intrinsic value (as of 05 January 2026) is ₹23.94 which is 314.19% higher the current market price of ₹5.78, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹5.92 Cr. market cap, FY2025-2026 high/low of ₹10.3/5.00, reserves of ₹-1.19 Cr, and liabilities of ₹3.50 Cr.
What is the Market Cap of Hindustan Bio Sciences Ltd?
The Market Cap of Hindustan Bio Sciences Ltd is 5.92 Cr..
What is the current Stock Price of Hindustan Bio Sciences Ltd as on 05 January 2026?
The current stock price of Hindustan Bio Sciences Ltd as on 05 January 2026 is ₹5.78.
What is the High / Low of Hindustan Bio Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hindustan Bio Sciences Ltd stocks is ₹10.3/5.00.
What is the Stock P/E of Hindustan Bio Sciences Ltd?
The Stock P/E of Hindustan Bio Sciences Ltd is 296.
What is the Book Value of Hindustan Bio Sciences Ltd?
The Book Value of Hindustan Bio Sciences Ltd is 0.84.
What is the Dividend Yield of Hindustan Bio Sciences Ltd?
The Dividend Yield of Hindustan Bio Sciences Ltd is 0.00 %.
What is the ROCE of Hindustan Bio Sciences Ltd?
The ROCE of Hindustan Bio Sciences Ltd is 2.95 %.
What is the ROE of Hindustan Bio Sciences Ltd?
The ROE of Hindustan Bio Sciences Ltd is 11.8 %.
What is the Face Value of Hindustan Bio Sciences Ltd?
The Face Value of Hindustan Bio Sciences Ltd is 2.00.